Please use this identifier to cite or link to this item:
Title: Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology.
Austin Authors: Doré, Vincent ;Bullich, Santiago;Rowe, Christopher C ;Bourgeat, Pierrick;Konate, Salamata;Sabri, Osama;Stephens, Andrew W;Barthel, Henryk;Fripp, Jurgen;Masters, Colin L ;Dinkelborg, Ludger;Salvado, Olivier;Villemagne, Victor L ;De Santi, Susan
Affiliation: The Florey Institute of Neurosciences and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
Life Molecular Imaging, GmbH, Berlin, Germany
Life Molecular Imaging Inc, Boston, MA, USA
Issue Date: Jun-2019
Date: 2019-05-14
Publication information: Alzheimer's & Dementia 2019; 15(6): 8007-816
Abstract: 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. Data from eighty-eight subjects (52 male subjects, aged 79.8 ± 10.6 years) who underwent antemortem 18F-florbetaben positron emission tomography scan and magnetic resonance imaging less than a year before neuropathological assessment at autopsy were evaluated. Image analysis was performed using the standard Centiloid (CL) statistical parametric mapping approach and CapAIBL®. Imaging results were compared against autopsy data. Against combined Bielschowsky silver staining and immunohistochemistry histopathological scores, statistical parametric mapping had 96% sensitivity, 96% specificity, and 95% accuracy, whereas magnetic resonance-less CapAIBL standardized uptake value ratioWhole Cerebellum had 94% sensitivity, 96% specificity, and 95% accuracy. Based on the combined histopathological scores, a CL threshold band of 19 ± 7 CL was determined. Quantification of 18F-florbetaben positron emission tomography scans using magnetic resonance-based and magnetic resonance-less CapAIBL® approaches showed high agreement, establishing a pathology-based threshold in CL.
DOI: 10.1016/j.jalz.2019.02.005
Journal: Alzheimer's & Dementia
PubMed URL: 31101517
Type: Journal Article
Subjects: Alzheimer's disease
Positron emission tomography (PET)
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 10, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.